{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008310","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.411249+00:00","generated_at":"2026-06-01T22:37:50.608378+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Capricor shareholders approve doubling authorized shares to 100M and elect all nine director nominees","bullets":["Amendment to increase authorized common shares from 50M to 100M approved (12.3M for, 8.7M against).","All nine director nominees elected, including CEO Linda Marbán and Frank Litvack.","Ratification of Rose, Snyder & Jacobs as auditor for FY 2024 approved (20.3M for).","Non-binding advisory vote on executive compensation approved (9.2M for, 2.0M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008310","json":"https://secwatch.observer/filing/0001558370-24-008310.json","markdown":"https://secwatch.observer/filing/0001558370-24-008310.md","text":"https://secwatch.observer/filing/0001558370-24-008310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/capr-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:37:50.608378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03ece6b68f96c4788666c889f313b4abd41a6b4d","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Linda Marbán, Ph.D. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"2cbc5a04781c8897be58a43eae118c3dab1f831c","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Michael Kelliher as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"3e74f80387f6c9750f7519e0ad7caf9db7297283","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Frank Litvack, M.D. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"779a70086fc16085a2b5b9cd00ab19fef0592dba","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Paul Auwaerter, M.D. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"afa30e0a761e77675eaee1b7583c80e51ee0e095","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Karimah Es Sabar as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"cace6061d3f13ff44e9b19d6265fea569519e728","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Earl M. Collier, Jr. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"df66e3db92ba15bd20661f3f02f43d4a82df7170","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of Philip Gotwals, Ph.D. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"eac06b7baaf6cc5b36db0dc75fc493e693efd1e1","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of David B. Musket as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"f28de815df8530364a45ee0846c0d6273bf90e09","claim":"CAPRICOR THERAPEUTICS, INC. shareholders approved Election of George W. Dunbar, Jr. as director at the 2024-05-14 meeting.","evidence_excerpt":"rsuant to Section 12(b) of the Act: ​ Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital Market ​ ​ ​ ​ ​ Item 5.07 Submission of Matters of a Vote of Security Holders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024008310/0001558370-24-008310-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}